PMC:4666274 / 20639-21443 JSONTXT

{"project":"TEST0","denotations":[{"id":"25994195-206-211-41386","span":{"begin":276,"end":277},"obj":"[\"17070475\"]"},{"id":"25994195-102-107-41387","span":{"begin":382,"end":383},"obj":"[\"8956167\"]"},{"id":"25994195-111-117-41388","span":{"begin":497,"end":499},"obj":"[\"15671279\"]"},{"id":"25994195-127-133-41389","span":{"begin":513,"end":515},"obj":"[\"16815872\"]"},{"id":"25994195-233-239-41390","span":{"begin":800,"end":802},"obj":"[\"20422195\"]"}],"text":"EOM atrophy is reported in a number of other neuromuscular disorders. Cranial nerve palsies (III, IV or VI) cause atrophy which is restricted to the muscle innervated by the affected nerve, thereby making it straight-forward to distinguish the affected muscle radiologically [6]. EOM atrophy is variably apparent in myasthenia gravis, but consistently seen in cases left untreated [7]. Radiological atrophy of clinically affected muscles has also been found in congenital fibrosis of EOMs type 1 [12] and type 2 [13] (now known to be dysinnervation syndromes). Taken together, these studies suggest that EOM atrophy is a feature of late-stage muscle pathology irrespective of the underlying cause, comparable to the atrophy of skeletal limb muscles on MRI in both neurogenic and myopathic disorders [14]."}

{"project":"0_colil","denotations":[{"id":"25994195-17070475-41386","span":{"begin":276,"end":277},"obj":"17070475"},{"id":"25994195-8956167-41387","span":{"begin":382,"end":383},"obj":"8956167"},{"id":"25994195-15671279-41388","span":{"begin":497,"end":499},"obj":"15671279"},{"id":"25994195-16815872-41389","span":{"begin":513,"end":515},"obj":"16815872"},{"id":"25994195-20422195-41390","span":{"begin":800,"end":802},"obj":"20422195"}],"text":"EOM atrophy is reported in a number of other neuromuscular disorders. Cranial nerve palsies (III, IV or VI) cause atrophy which is restricted to the muscle innervated by the affected nerve, thereby making it straight-forward to distinguish the affected muscle radiologically [6]. EOM atrophy is variably apparent in myasthenia gravis, but consistently seen in cases left untreated [7]. Radiological atrophy of clinically affected muscles has also been found in congenital fibrosis of EOMs type 1 [12] and type 2 [13] (now known to be dysinnervation syndromes). Taken together, these studies suggest that EOM atrophy is a feature of late-stage muscle pathology irrespective of the underlying cause, comparable to the atrophy of skeletal limb muscles on MRI in both neurogenic and myopathic disorders [14]."}

{"project":"2_test","denotations":[{"id":"25994195-17070475-29351462","span":{"begin":276,"end":277},"obj":"17070475"},{"id":"25994195-8956167-29351463","span":{"begin":382,"end":383},"obj":"8956167"},{"id":"25994195-15671279-29351464","span":{"begin":497,"end":499},"obj":"15671279"},{"id":"25994195-16815872-29351465","span":{"begin":513,"end":515},"obj":"16815872"},{"id":"25994195-20422195-29351466","span":{"begin":800,"end":802},"obj":"20422195"}],"text":"EOM atrophy is reported in a number of other neuromuscular disorders. Cranial nerve palsies (III, IV or VI) cause atrophy which is restricted to the muscle innervated by the affected nerve, thereby making it straight-forward to distinguish the affected muscle radiologically [6]. EOM atrophy is variably apparent in myasthenia gravis, but consistently seen in cases left untreated [7]. Radiological atrophy of clinically affected muscles has also been found in congenital fibrosis of EOMs type 1 [12] and type 2 [13] (now known to be dysinnervation syndromes). Taken together, these studies suggest that EOM atrophy is a feature of late-stage muscle pathology irrespective of the underlying cause, comparable to the atrophy of skeletal limb muscles on MRI in both neurogenic and myopathic disorders [14]."}

{"project":"MyTest","denotations":[{"id":"25994195-17070475-29351462","span":{"begin":276,"end":277},"obj":"17070475"},{"id":"25994195-8956167-29351463","span":{"begin":382,"end":383},"obj":"8956167"},{"id":"25994195-15671279-29351464","span":{"begin":497,"end":499},"obj":"15671279"},{"id":"25994195-16815872-29351465","span":{"begin":513,"end":515},"obj":"16815872"},{"id":"25994195-20422195-29351466","span":{"begin":800,"end":802},"obj":"20422195"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"EOM atrophy is reported in a number of other neuromuscular disorders. Cranial nerve palsies (III, IV or VI) cause atrophy which is restricted to the muscle innervated by the affected nerve, thereby making it straight-forward to distinguish the affected muscle radiologically [6]. EOM atrophy is variably apparent in myasthenia gravis, but consistently seen in cases left untreated [7]. Radiological atrophy of clinically affected muscles has also been found in congenital fibrosis of EOMs type 1 [12] and type 2 [13] (now known to be dysinnervation syndromes). Taken together, these studies suggest that EOM atrophy is a feature of late-stage muscle pathology irrespective of the underlying cause, comparable to the atrophy of skeletal limb muscles on MRI in both neurogenic and myopathic disorders [14]."}